Anupam Rama

Ashwani Verma

Cory Kasimov

David Amsellem

Laura Chico

Marc Goodman

Myles Minter

Paul Matteis

Tazeen Ahmad

Akash Tewari

Brian Abrahams

Brian Skorney

Evan Seigerman

Jay Olson

Mohit Bansal

Philip Nadeau

Ami Fadia

Chris Shibutani

Sumant Kulkarni

Uy Ear

Yatin Suneja

Carter L. Gould

Corinne Johnson

Danielle Brill

David Huang

Jeff Hung

Jeffrey Hung

Joshua Schimmer

Leonid Timashev

Michael Riad

Phil Nadeau

Sean Laaman

- Neurocrine Biosciences expects **INGREZZA sales to reach $2.5 billion** in 2025.  **[914475_tx_379747_0]** 
- The launch of **Chrinesity** has been strong, marking the first new medicine for congenital adrenal hyperplasia in over seventy years.  **[914475_tx_379747_0]** 
- The company has initiated two major Phase 3 programs: **osavampitur for major depressive disorder** and a **muscarinic program for schizophrenia**, with plans to initiate a trial for bipolar mania later in 2025.  **[914475_tx_379747_0]** 
- Neurocrine has increased INGREZZA's Medicare coverage to **north of 70%** of the TD market, which has led to record new patient starts in Q1 and Q2 2025, despite a **5% net price impact** for the year.  **[914475_tx_379747_1]** 
- Under the IRA, INGREZZA's potential negotiated price range is **25-34%**, expected to be implemented in **2029**.  **[914475_tx_379747_3]**

Neurocrine Biosciences Provides 2025 Outlook and Pipeline Updates

NEUROCRINE BIOSCIENCES (NBIX)